Regulatory Index News w/c 31 Dec 2018

Here is a selection of this week's latest news from around the world

                                                                                                                                                                                                                                  

NHS England to fund Actelion's Uptravi

Actelion has announced that NHS patients in England, who have the rare, incurable and devastating disease pulmonary arterial hypertension (PAH) can now be treated with Uptravi (selexipag).

To read more follow this PharmaTimes link 

 

Bristol-Myers to buy Celgene in industry-shaking $74B deal

Bristol-Myers Squibb will acquire Celgene in a $74 billion cash-and-stock deal that would recast the top ranks of the pharmaceutical industry, creating a powerful company with leading positions in immuno-oncology and the treatment of blood cancers.

To read more follow this BioPharmaDive link

     
 

Drugmakers open new year with price increases on dozens of medicines

Several major drugmakers, including Allergan, Bristol-Myers Squibb and Eli Lilly, increased prices on a number of their drugs Jan. 1, holding with typical industry practice despite continuing scrutiny of rising pharmaceutical costs.

To read more follow this BioPharmaDive link

 

Sprycel combo gets FDA approval

The US Food and Drug Administration has approved a new treatment for children one year of age and older, facing a type of blood cancer known as Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) when used in combination with chemotherapy.

To read more follow this PharmaTimes link 

     
 

Pfizer, Merck to terminate Phase III Bavencio study

Pfizer and Merck KGaA have announced that they will be terminating the Phase III JAVELIN Ovarian 100 study of Bavencio (avelumab), as the data did not support the study's initial hypothesis.

To read more follow this PharmaTimes link 

 

Merck licenses diabetes, NASH treatment from NGM

Merck & Co. exercised a licensing option with NGM Biopharmaceuticals on a monoclonal antibody being tested to treat nonalcoholic steatohepatitis (NASH) and Type 2 diabetes, the companies announced Thursday. 

To read more follow this BioPharmaDive link

 

L O

Author

Lorna Osborn

Date Published

04th January 2019

Come and join our community!

We are ready and waiting for you

We use cookies. By continuing to browse the site or closing this message you are agreeing to our Terms and Privacy Policy

ACCEPT and Hide This Message